微信公众号

官网二维码

中国癌症防治杂志 ›› 2026, Vol. 18 ›› Issue (1): 122-128.doi: 10.3969/j.issn.1674-5671.2026.01.15

• 综述 • 上一篇    下一篇

溶质载体转运体介导结直肠癌恶性进展的机制及临床应用潜力

  

  1. 内蒙古医科大学赤峰临床医学院;赤峰市医院病理科
  • 出版日期:2026-02-25 发布日期:2026-03-27
  • 通讯作者: 童玲 E-mail:tongling007@163.com
  • 基金资助:
    赤峰市自然科学科研课题(SZR2025042)

Mechanisms and clinical application potential of solute carrier transporters in colorectal cancer

  • Online:2026-02-25 Published:2026-03-27

摘要: 溶质载体(solute carrier, SLC)转运体家族是维持细胞物质代谢稳态的重要跨膜蛋白系统,广泛参与氨基酸、葡萄糖、脂质、金属离子及维生素等物质的跨膜转运。近年来研究表明,多种SLC转运体在结直肠癌(colorectal cancer, CRC)中异常表达,通过介导肿瘤代谢重编程、促进侵袭转移、调控肿瘤免疫微环境以及参与治疗耐药等多重机制,推动肿瘤恶性进展。本文系统综述SLC转运体在CRC发生发展中的分子机制,重点总结其在代谢调控、免疫逃逸及治疗应答中的作用,并进一步探讨其作为诊断、预后生物标志物及潜在治疗靶点的临床应用价值,以期为CRC的精准诊疗提供理论依据。

关键词: 结直肠癌, 溶质载体转运体, 代谢重编程, 肿瘤免疫微环境, 治疗耐药

Abstract: The solute carrier (SLC) transporter family constitutes a vital transmembrane protein system for maintaining cellular metabolic homeostasis. It is extensively involved in the transmembrane transport of diverse substances, including amino acids, glucose, lipids, metal ions and vitamins. In recent years, numerous studies have demonstrated that multiple SLC family members are aberrantly expressed in colorectal cancer (CRC). These aberrantly expressed SLC transporters drive the malignant progression of tumors through multiple mechanisms, such as mediating tumor metabolic reprogramming, promoting tumor invasion and metastasis, regulating the tumor immune microenvironment, and participating in therapeutic resistance. This article systematically reviews the molecular mechanisms underlying the involvement of SLC transporters in the initiation and progression of CRC, with a focus on summarizing their roles in metabolic regulation, immune evasion and therapeutic response of CRC. It further explores their clinical application value as diagnostic and prognostic biomarkers as well as potential therapeutic targets, aiming to provide a theoretical basis for the precision diagnosis and treatment of colorectal cancer.

Key words: Colorectal cancer, Solute carrier transporters, Metabolic reprogramming, Tumor immune microenvironment, Therapeutic resistance

中图分类号: 

  • R735.3